Researchers have extensively studied targeted therapies for ARID1A‐mutated gastric cancer, including inhibitors of poly (ADP‐ribose) polymerase (PARP), PI3K/AKT, ATR, enhancer of EZH2 and histone deacetylase (HDAC).81, 94, 95, 96, 97. Here, ARID1A is linked to gastric cancer.